The 30 mg pioglitazone tablet was recently introduced in Korea; no study has yet compared its glucose-lowering or weight gain effects to the 15 mg tablet in Korean patients with type 2 diabetes mellitus (T2DM). Methods: The electronic medical records of 45 patients with T2DM with glycated hemoglobin (HbA1c) levels > 7.0%, despite taking 15 mg/day pioglitazone and a stable dose of other diabetes drugs for 3 months, were retrospectively reviewed. Results: After dose up-titration, HbA1c levels decreased at 3-and 6-month follow-ups compared with baseline (8.5% at baseline vs. 8.2% at 3 months vs. 7.9% at 6 months; baseline vs. 3 months, P = 0.106; baseline vs. 6 months, P = 0.005; 3 months vs. 6 months, P = 0.096). In the subgroup analysis of 36 patients taking pioglitazone, sulfonylurea, and metformin, HbA1c levels also decreased at 3-and 6-month follow-ups compared with baseline (8.5 % vs. 8.2 % vs. 7.9%; baseline vs. 3 months, P = 0.289; baseline vs. 6 months, P = 0.014; 3 months vs. 6 months, P = 0.232). There was no significant body weight change (70.8 kg vs. 70.7 kg vs. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Pioglitazone, a type of thiazolidinedione, is known to improve insulin sensitivity, glycemic control, dyslipidemia, hypertension, and microalbuminuria in patients with type 2 diabetes mellitus (T2DM) [1] .
Pioglitazones are effective as combination therapy in patients who have failed monotherapy and are included as an option in the American Diabetes Association consensus algorithm [2] . The 2011 Clinical Practice Guidelines for Type 2 Diabetes by the Korean Diabetes Association recommended metformin as the initial preferred monotherapy; in cases with glycated hemoglobin (HbA1c) levels greater than 7.5%, they recommended metformin-based dual therapies with sulfonylurea, pioglitazone, or dipeptidyl peptidase 4 inhibitors as an initial regimen [3] .
Although several studies in Western countries and Japan have shown the glucose-lowering effects of a pioglitazone dosage of 30 mg [4] [5] [6] [7] [8] [9] [10] , until 2012 only pioglitazone 15 mg/day was available in Korea. Because pioglitazone 30 mg/day was not available until January 2013, there are no data on the glucose-lowering efficacy of pioglitazone 30 mg/day in Korea. It is possible that differences in the glucose-lowering efficacy of pioglitazone 30 mg/day exist based on ethnicity.
We aimed to examine the efficacy and safety of pioglitazone when the dose was up-titrated to 30 mg in subjects with T2DM with inadequate glycemic control on 15 mg of pioglitazone combined with other oral hypoglycemic agents.
MATERIALS AND METHODS

Study design and participants
The present study is a single-arm, retrospective study. Medical records of patients with T2DM who visited the Inje University Ilsan Paik Hospital Diabetes-Endocrinology Center between January and June 2013 were reviewed. In this analysis, we excluded subjects 25 years or younger in age and those with a history of diabetic ketoacidosis in order to minimize the possibility of including type 1 diabetics in the study population. Although we did not evaluate for the presence of autoantibodies of type 1 diabetes in our subjects, we assumed that the diabetics identified in our study were type 2 diabetics because the incidence of autoantibodies in late-onset diabetes is markedly low in the Korean population [11] . In the Inje University Ilsan Paik Hospital database, patients with T2DM who underwent a dose up-titration of pioglitazone from 15 to 30 mg for 24 weeks were analyzed. We enrolled a study population of patients 71.0 kg). Conclusion: Up-titrating from 15 mg to 30 mg of pioglitazone in patients with inadequate glycemic control (HbA1c > 9%) who were also taking sulfonylurea and metformin showed additive glucose-lowering effects without significant weight gain in Korean patients with T2DM. Olympus, Tokyo, Japan). HbA1c was measured using a high-performance liquid chromatography method and a HLC-723 G8 chromatograph (Tosoh Corp., Tokyo, Japan; coefficient of variation 1.66%). 
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Characteristics of the study population (Table 1)
Among the 45 patients included in the study, 29 patients (64.4%) were men and 16 patients (35.6%) were women (age, 60.6 ± 1.49 years old; BMI, 25.9 ± 0.41 kg/m 2 ; baseline FPG level, 164.3 ± 5.96 mg/dL, and duration of diabetes, 14.9 ± 1.18 years) ( Table   1 ). Five participants (11.1%) were administered sulfonylurea only, 2 participants (4.4%) were administered metformin only, 36 participants (80.0%) were administered both sulfonylurea and metformin, and 2 participants (4.4%) were administered both sulfonylurea and dipeptidyl peptidase 4 inhibitor.
Change in HbA1c and FPG (Fig. 1)
In the total study population, compared with baseline measurements, HbA1c continually decreased significantly for 6 months (8.5 ± 0.1% at baseline vs. 8.2 ± 0.1% at 3 months vs. 7.9 ± 0.1% at 6 months; baseline vs. 3 months, P = 0.106; baseline vs. 6 months, P = 0.005; 3 months vs. 6 months, P = 0.096). FPG also significantly decreased (164 ± 6 mg/ dL at baseline vs. 146 ± 7 mg/dL at 3 months vs. 146 
Determinants for responders (Table 2 and 3)
When the responder was defined as decrease of HbA1c ≥ 1.0% for 6 months on pioglitazone up- Until now, only one study reported the efficacy and safety of pioglitazone according to dose up-titration, which examined the effects of an increased dose of pioglitazone from 15 to 30 mg/day on its glucoselowering efficacy in Japanese diabetes patients undergoing hemodialysis [12] . In that study, the patients were administered pioglitazone 15 mg daily with their morning meal for the first 4 weeks.
Body weight and other adverse events
Subsequently, the doses were titrated by doubling the dose to a maximum of 30 mg/day. During a 24-week period of treatment, HbA1c levels decreased from 6.8% at baseline to 6.1% after 4 weeks and the decreases continued for 24 weeks of therapy without interdialytic body weight gain. There are some limitations to this study. First, it is a small sized study with a limited number of enrollees and restricted to a specific geographic area. Second, it is a retrospective study that used electronic medical record data. Especially there were some possibilities that minor adverse effects could be ignored with limited study design. Therefore, the finding of no increased side effect on pioglitazone up-titration should be confirmed in another prospectively-designed study.
In conclusion, up-titrating to 30 mg pioglitazone from 15 mg in patients with inadequate glycemic control showed additive glucose-lowering effects without significant weight gain in Korean patients with T2DM, especially in cases with poorer glycemic control (HbA1c > 9%), taking sulfonylurea and metformin; however, another prospective, large-sample study is required.
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